Due to scheduled maintenance work on our servers, there may be short service disruptions on this website between 11:00 and 12:00 CEST on March 28th.

Special Issues

Antibodies publishes Special Issues to create collections of papers on specific topics, with the aim of building a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors, who are experts on the topic and all Special Issue submissions follow MDPI's standard editorial process. The journal’s Editor-in-Chief and/or designated Editorial Board Member will oversee Guest Editor appointments and Special Issue proposals, checking their content for relevance and ensuring the suitability of the material for the journal. The papers published in a Special Issue will be collected and displayed on a dedicated page of the journal’s website. Further information on MDPI's Special Issue policies and Guest Editor responsibilities can be found here. For any inquiries related to a Special Issue, please contact the Editorial Office.

Section
Search by Title/Keyword
 
Order results
Display
Results per page
Antiphospholipid Antibodies: Beyond Biomarkers submission deadline 25 May 2026 | Viewed by 341 | Submission Open
Keywords: autoimmunity; antiphospholipid syndrome; antiphospholipid antibodies; lupus anticoagulant; anticardiolipin antibody; anti-beta-2-glycoprotein 1 antibody; autoimmune diseases
(This special issue belongs to the Section Humoral Immunity)
Antibody-Mediated Rejection in Kidney Transplantation
edited by Kazuhiro Iwadoh and
submission deadline 25 Jun 2026 | 3 articles | Viewed by 9796 | Submission Open
Keywords: AMR treatment; anti-blood type antibodies; antibody-mediated rejection (AMR); C4d deposition; desensitization strategies; donor-specific antibodies (DSA); kidney transplantation; late graft failure; non-HLA antibodies; subclinical AMR detection
(This special issue belongs to the Section Humoral Immunity)
A Festschrift Celebrating Dr. Dimiter Stanchev Dimitrov: Antibodies, Innovation, and Impact on Infectious Disease and Cancer Research submission deadline 30 Jun 2026 | 10 articles | Viewed by 26005 | Submission Open
Keywords: monoclonal antibodies; innovative therapies; full-size antibodies; antibody fragments
Antibody and Autoantibody Specificities in Autoimmunity submission deadline 30 Jun 2026 | 4 articles | Viewed by 15770 | Submission Open
Keywords: autoimmunity; autoantibodies; biological therapy; post-translational modified autoantigens
Therapeutic Antibodies: New Trends in Discovery, Developability and Characterization
edited by and
submission deadline 20 Oct 2026 | 6 articles | Viewed by 16295 | Submission Open
Keywords: antibody lead candidates selection; epitope prediction and mapping; developability assessment; antibody engineering; mode-of-action elucidation; host– cell analysis
Antiviral Antibody Immune Responses in the Context of Vaccination and Infection submission deadline 20 Oct 2026 | 1 articles | Viewed by 3238 | Submission Open
Keywords: virus; B lymphocytes; antibodies; viral vaccines; functional assays; physicochemical characterization; BCR; affinity maturation; avidity; affinity; protection; human; veterinary
(This special issue belongs to the Section Humoral Immunity)
Immune Phenomena in Autoimmune Skin Disorders
edited by and Justyna Gornowicz-Porowska
submission deadline 20 Nov 2026 | Viewed by 59 | Submission Open
Keywords: pemphigus; pemphigoid; dermatitis herpetiformis; autoimmune connective tissue diseases; vasculitides
(This special issue belongs to the Section Antibody-Based Therapeutics)
The Role of Antibodies in Combating Bacterial Infections and Antibiotic Resistance
edited by and Pontus Nordenfelt
submission deadline 30 Nov 2026 | Viewed by 340 | Submission Open
Keywords: anti-infectives; monoclonals; bi-specific antibodies; therapeutic antibodies; antibody engineering; antimicrobial; mAb; immunotherapy; nanobodies; immunoglobulins; IVIG; Fc-engineering; glycoengineering
(This special issue belongs to the Section Antibody-Based Therapeutics)
Back to TopTop